Malaria vaccine - Osaka University

Drug Profile

Malaria vaccine - Osaka University

Alternative Names: BK SE36/CpG; BK-SE36

Latest Information Update: 19 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Osaka University
  • Developer Nobelpharma; Osaka University; Research Foundation for Microbial Diseases of Osaka University
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Falciparum malaria

Most Recent Events

  • 08 Feb 2017 Nobelpharma terminates a phase I trial in Falciparum malaria (In children, In infants, Prevention) in Burkina Faso (IM) (SC) (PACTR201411000934120)
  • 16 Dec 2016 Nobelpharma plans a clinical trial for Malaria in Burkina Faso (PACTR201701001921166)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top